Linvoseltamab Generates Responses in Newly Diagnosed Myeloma
The LINKER-MM4 trial enrolled 45 adult patients with previously untreated, symptomatic multiple myeloma. The cohort included both transplant-eligible (62.2%) and transplant-ineligible patients. As of the September 15, 2025, data cutoff, the median follow-up was 11.2 months for the phase 1a dose-escalation cohort and 4.8 months for the phase 1b dose-expansion cohort.
Responses were rapid, with a median time to partial response or better of 1.2 months.
Among the 43 patients evaluable for response:
- 56% achieved a very good partial response (VGPR) or better.
- 26% achieved a complete response (CR) or better.
- 82% of patients who achieved a CR did so within 6 months of treatment initiation.
The efficacy data indicated a dose-dependent response. Patients in the 200 mg cohort (n = 21) demonstrated higher response rates compared with the 50 mg cohort (n = 20), with 86% vs 70% ORR, respectively. At the time of analysis, all patients remained progression-free.